TL;DR
Get workout gear delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A study in Nature Communications links higher blood levels of imidazole propionate (ImP), a molecule produced by some gut bacteria, with Alzheimer’s-related biological markers and faster cognitive decline. Mouse experiments found effects on amyloid and tau, but the human findings are associations and do not show that ImP causes Alzheimer’s disease or that lowering it prevents decline.
Researchers report that imidazole propionate (ImP), a molecule produced by some gut bacteria, may be linked to Alzheimer’s-related brain changes and faster cognitive decline. In a study published in Nature Communications, ImP increased abnormal amyloid and tau accumulation in mice, while analysis of nearly 1,200 people found that higher blood levels were associated with dementia-related biological markers and faster decline on cognitive tests; the human results do not establish that ImP causes the disease.
The team, led by University of Wisconsin–Madison researchers Barbara Bendlin and Federico Rey, studied ImP because it is made by certain gut bacteria and can enter the bloodstream. Its production varies among people. Although ImP-producing bacteria are present in many people, Rey said they are generally not abundant in most people, and their low numbers do not necessarily mean they have no effect on the body.
In experiments with mice, ImP that reached the brain was linked to increased accumulation of beta-amyloid and tau, proteins associated with Alzheimer’s disease. The researchers describe this as evidence that the molecule could affect processes relevant to brain health. Animal findings, however, do not show that the same effects occur in people or establish that ImP is a cause of Alzheimer’s.
For the human analysis, the researchers examined blood samples from almost 1,200 participants in the Wisconsin Registry for Alzheimer’s Prevention and studies run through the Wisconsin Alzheimer’s Disease Research Center. Higher ImP concentrations were associated with biological markers of abnormal proteins and impaired neuron function. Participants with the highest levels also showed faster cognitive decline over time, according to their repeated test results. The report does not give a specific size for that difference in decline.
A Potential Gut-to-Brain Pathway
The study adds a specific molecule to research into how the gut microbiome may relate to brain health. Rather than relying only on broad differences in which microbes are present, the researchers investigated a substance those microbes produce and measured it in blood. That could help scientists test more directly whether gut activity and circulating molecules contribute to changes in the brain.
The possible treatment implication is still preliminary. If further studies show that ImP plays a causal role, reducing its levels could become a research target for prevention or treatment. Bendlin compared the idea to cholesterol-lowering drugs, but no ImP-lowering treatment was tested or shown to reduce Alzheimer’s risk in this study. The findings do not support changing diet or medication to lower ImP now.
The distinction matters to readers because an association with faster decline is not a prediction of an individual’s future health. The study identifies a candidate pathway for more research; it does not establish a new diagnostic test, quantify a person’s risk, or show that lowering ImP would slow dementia.
gut health supplements for brain health
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From Gut Microbes to ImP
Bendlin and Rey’s team has studied differences in gut microorganisms between people with Alzheimer’s disease and healthy individuals for nearly a decade. The current work shifts attention toward ImP, a bacterial product, and whether it may help explain how gut-related differences could be connected to the brain.
ImP is produced as some bacteria generate energy from histidine, an amino acid people need and obtain from many foods, including protein-rich foods. The researchers say this makes simply avoiding histidine an unsuitable conclusion from the findings. Bendlin said that improving diet may generally help health, but reducing ImP is not as simple as cutting out a particular food.
Earlier research has linked ImP to type 2 diabetes and coronary artery disease. The new study extends the investigation to brain-related measures. Researchers from the University of California, Los Angeles, and the University of Gothenburg also contributed. The work received support from the Wisconsin Partnership Program, the National Institutes of Health and the U.S. Department of Agriculture.
“Since then, we’ve been trying to figure out how this difference in the gut perhaps leads to changes in the brain.”
— Barbara Bendlin, University of Wisconsin–Madison professor of medicine
Causation and Treatment Remain Open
The human data show associations, not proof of cause. It remains unclear whether elevated ImP contributes to cognitive decline, reflects other health or biological factors, or is linked to both through another mechanism. The mouse results offer experimental evidence about amyloid and tau in animals, but do not resolve that question in people.
The study also identified a genetic variation associated with substantially higher blood ImP levels. About 43% of participants carried the variation. The researchers suspect it may affect how effectively the kidneys clear ImP from the blood, but the report does not establish that mechanism. The variation’s relationship to Alzheimer’s risk also needs further study; the research does not show that genetic testing can predict an individual’s outcome.
No clinical trial tested an ImP inhibitor, and the study did not show that dietary changes lower ImP or alter dementia risk. The report does not specify a proven target blood level, a practical screening method, or how large a treatment effect might be. Those questions remain open.
Testing ImP as a Treatment Target
The next step is to determine whether ImP directly contributes to Alzheimer’s-related changes in people and whether safely lowering its blood levels can affect those changes. Further research will also need to clarify how the genetic variation relates to ImP clearance and whether the apparent kidney mechanism is correct.
Any proposed inhibitor would need to be developed and evaluated in clinical studies before researchers could say whether it reduces risk or slows cognitive decline. Until then, the finding is a research lead, not medical advice. The study offers no basis for avoiding histidine-containing foods, changing prescribed treatment, or using an untested product to lower ImP.
Key Questions
Does this study prove that ImP causes Alzheimer’s disease?
No. The human results show that higher blood ImP was associated with Alzheimer’s-related markers and faster cognitive decline. They do not prove that the molecule causes the disease. Mouse experiments found increased amyloid and tau accumulation, but animal results cannot establish the same effect in people.
What is imidazole propionate?
Imidazole propionate (ImP) is a molecule produced by certain gut bacteria as they generate energy from histidine, an amino acid needed by the body. The molecule can enter the bloodstream, and its levels vary among people.
Should people avoid foods containing histidine?
The researchers do not recommend that. Histidine is an essential amino acid found in many foods, and the study did not test dietary changes as a way to lower ImP or prevent cognitive decline. It is not evidence to eliminate eggs, meat or other foods.
Is there a treatment that lowers ImP?
The study did not test an ImP-lowering drug or show that lowering the molecule changes Alzheimer’s risk. Researchers say a targeted inhibitor could be a future possibility, but clinical testing would be needed before its safety or benefit could be known.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
